Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2006

View Archived Issues

Medarex looks back on achievements

Cangrelor demonstrates advantages over abciximab in patients undergoing PCI

Mepolizumab decreases eosinophilia in hypereosinophilic syndromes, esophagitis

Novel anti-HGF MAb L2G7 exhibits profound effects in mice bearing intracranial glioma xenografts

Targeted Genetics supports plans for 2006 through new financing

Dusa closes acquisition of Sirius Laboratories

Pharmos to acquire Vela Pharmaceuticals

Enrollment completed in SPIRIT III study of Xience V stent

Roche expands manufacturing network for production of Tamiflu

GenVec expands TNFerade phase II study into phase II/III trial

Edison and university partners establish mitochondrial disease collaboration

AdvaTab Cetirizine completes pharmacokinetic study

Phase II pilot study assesses Oxycyte in traumatic brain injury

Novavax collaborative HIV program receives additional funding

LymphoSign completes preclinical testing of LS-104

V-1003 superior to Vicodin for pain relief

Significant decline in HBV viral load in pradefovir study

Sativex produces improvement in MS-related spasticity

Human Genome Sciences reports new phase II data for Albuferon

ALK5 inhibitor a novel therapeutic approach for the treatment of fibrosis

Recent patents impart new therapeutic agents for cancer

New agents for treating thrombocythemia reported in recent Shire patent

Targeting the M. tuberculosis proteasome for novel tuberculosis therapies

ARRY-649: A novel, highly potent KSP inhibitor from Array BioPharma

The glycolytic enzyme GAPDH as a target for neuroprotection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...